Connect with us

Technology

Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board

Published

on

Dr Hoekema brings over four decades of successful biotech and life science leadershipDr Cora Griffin appointed to head up business development, follows recent appointment of Simon Jones as CFO/COONew hires to accelerate ambition to turbocharge the discovery platform, develop innovative therapeutic pipeline and expand pharma relationships

SOUTHAMPTON, England, Oct. 2, 2024 /PRNewswire/ — Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the further strengthening of its leadership team with the appointments of Andre Hoekema as Chair of the Board and Cora Griffin as Head of Business Development. The appointments continue the strong momentum at Curve following the recent appointment of Simon Jones as CFO/COO.

Dr Hoekema is a highly experienced and successful biotech executive with 40 years’ experience in the industry. He served as Chief Business Officer and member of the Executive Committee at Galapagos Pharma for 18 years, with responsibility spanning M&A, business development and IP. During his time at Galapagos, he led multiple pharma partnerships, acquisitions and divestments, including two landmark deals with Gilead. He was also part of the team that completed successful IPOs on Euronext (2005) and Nasdaq (2015). Andre serves as a member of the supervisory advisory boards of Artax Biopharma, Fibrocor Therapeutics and Mimetas BV.

Curve has also appointed Cora Griffin, an accomplished life sciences business development professional and entrepreneur, as Head of Business Development. Dr Griffin has considerable experience in developing and implementing portfolio strategies from start-ups to large pharmaceutical companies. She was previously Head of Business Development & Alliance Management at ReViral and was instrumental in the acquisition by Pfizer for US$525 million. Cora served as Anti-infectives Strategy Lead at Pfizer, responsible for the Infectious Diseases portfolio strategy for the Research Unit. She is a Jury Member for the EIC Accelerator program for the European Innovation Council and Board Observer at Oppilotech.

Simon Kerry, Chief Executive Officer of Curve Therapeutics, said: “Following the significant Series A financing, we are building a world-class leadership team to turbocharge our proprietary discovery platform and rapidly progress our pipeline. Andre’s wealth of experience in the sector and significant track record, and Cora’s visionary outlook and strategic nous, will be invaluable as we grow the business and progress our lead candidate towards the clinic. We are well placed to accelerate our ambition to build out the pipeline and work with strategic partners to address complex and challenging disease targets and improve patient outcomes.”

Andre Hoekema, PhD, new Chair of Curve Therapeutics, commented: “Curve is an ambitious and innovative biotech with the mission to revolutionize the drug discovery space with its Microcycle discovery platform. Through its pioneering and truly unique approach, Curve is building an innovative therapeutic pipeline and establishing strong relationships with major pharma. I look forward to working with Simon and the leadership team to help the Company progress to the next stage of growth.”

About Curve Therapeutics 

Curve Therapeutics is a private biotechnology company pioneering a revolutionary intracellular screening platform to enable the discovery of innovative therapeutics that address complex and challenging disease targets with the potential to transform the lives of patients. Curve originated from world-leading Microcycle research conducted by Professor Tavassoli’s group in the Department of Chemistry at the University of Southampton, UK. Curve is backed by blue chip investors including Advent Life Sciences, Epidarex Capital, Pfizer Ventures, Columbus Venture Partners and British Patient Capital. Curve has a US$1.7bn global research collaboration with MSD the trade name of Merck & Co., Inc., Kenilworth, NJ USA, to discover and validate modulators of up to five therapeutic targets using its Microcycle technology, initially for oncology and neurology indications. For more information visit: www.curvetx.com.

About Curve’s Microcycle platform

Curve has developed an IP-protected, mammalian cell platform technology, for functional screening and enrichment of diverse hexameric cyclic peptide Microcycle libraries, to identify those library members that have the desired biological activity against a therapeutic target. Curve’s platform allows direct screening for biologically active library members inside mammalian cells and facilitates small molecule hit-to-lead programs. A key advantage of the technology is that both the library and the target are present in all their native conformations within a cell. Uniquely, the compact size and rigid structure of Microcycles enables the design of non-peptide small molecule leads. The disease agnostic discovery platform can be used for a wide range of therapeutically relevant targets, including protein-protein and protein-DNA interactions, and has been used by Curve to develop a pipeline of cancer programs against targets including a dual HIF-1/HIF-2 inhibitor and an inhibitor of ATIC homodimerization.

View original content:https://www.prnewswire.co.uk/news-releases/curve-therapeutics-further-strengthens-leadership-team-with-the-appointment-of-andre-hoekema-as-new-chair-of-board-302264539.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

iMarketKorea Signs Two MOUs with Vietnam’s Phu Tho Provincial People’s Committee and BIDV

Published

on

By

Participates in Korea-Vietnam Economic Delegation

Accelerates development of an industrial park in Phu Tho Province near Hanoi, while attracting advanced manufacturing companies and building a supply chain ecosystemPlans parallel development of an Inland Container Depot (ICD) to strengthen logistics competitivenessExpands discussions with Bank for Investment and Development of Vietnam (BIDV) on financial support measures and new business opportunities

HANOI, Vietnam and SEOUL, South Korea, April 27, 2026 /PRNewswire/ — iMarketKorea, a leading industrial materials distribution company led by CEO Kim Hak-jae, announced that it has signed two Memoranda of Understanding (MOUs) with the Phu Tho Provincial People’s Committee and Bank for Investment and Development of Vietnam during the MOU signing session at the Korea-Vietnam Business Forum, hosted by Korea’s Ministry of Trade, Industry and Energy and the Korea Chamber of Commerce and Industry. The company participated in the official Korea-Vietnam economic delegation.

As Vietnam’s investment environment continues to advance, cooperation in production infrastructure such as industrial parks has become increasingly important. Based on prior discussions with Phu Tho Province, iMarketKorea formalized this partnership through the latest agreements.

Located near Noi Bai International Airport, Phu Tho Province is emerging as a strategic logistics hub and an attractive production base for global companies. The province recorded 10.52% gross regional domestic product (GRDP) growth in 2025, ranking fourth among Vietnam’s provinces.

Through the agreement, iMarketKorea plans to develop a national industrial park in Phu Tho Province and actively attract global manufacturing companies. The company also aims to build a supply chain-driven industrial ecosystem by strengthening collaboration among related businesses centered around the industrial complex.

To enhance logistics competitiveness, iMarketKorea will also pursue the development of an Inland Container Depot (ICD) with bonded warehousing functions. An ICD is an inland logistics hub enabling customs clearance and cargo handling. When integrated with the industrial park, it is expected to improve import-export efficiency and strengthen the region’s attractiveness to manufacturers.

Kim Hak-jae, CEO of iMarketKorea, said, “This agreement establishes the foundation for integrated production and logistics infrastructure. Through cooperation with the Phu Tho provincial government and BIDV, we plan to establish a one-stop support system covering administration, finance, legal matters, and taxation. We will also create an environment where high-tech parts and materials companies can effectively utilize local incentives and gradually expand future cooperation.”

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/imarketkorea-signs-two-mous-with-vietnams-phu-tho-provincial-peoples-committee-and-bidv-302753801.html

SOURCE iMarketKorea

Continue Reading

Technology

Global Customers Are Taking a Closer Look at Focused Photonics Inc.

Published

on

By

HANGZHOU, China, April 24, 2026 /PRNewswire/ — For scientific instrument companies competing globally, differentiation increasingly depends on more than product specifications alone. Customers are looking beyond performance claims to assess whether a company can consistently translate technology into manufacturable products, proven applications, reliable delivery and long-term service support.

That shift was evident during Focused Photonics Inc.’s (FPI) Global Customer Experience Day 2026 in Hangzhou, where customers and partners from dozens of countries visited the company’s Qingshanhu Innovation Base, headquarters and live application sites. For many attendees, the event offered a closer look at how a China-headquartered scientific instrument company is building capabilities across R&D, manufacturing, systems integration and lifecycle support.

At Qingshanhu Innovation Base, visitors saw key stages of FPI’s operations firsthand, including engineering, precision manufacturing, system integration, testing and service readiness. For many international customers, these visits are less about viewing a production line and more about assessing execution: whether a supplier has the engineering discipline, manufacturing depth and support infrastructure required to deliver consistently in real operating environments.

This is becoming increasingly important across the industry. As customer expectations evolve, competition is moving beyond stand-alone instrument performance toward integrated solutions, automation, data integrity, compliance and lifecycle value. In industrial and environmental applications in particular, uptime, stability and workflow fit often matter as much as analytical capability.

At its global customer conference, FPI outlined how it is responding to that transition, highlighting continued investment across environmental monitoring, industrial process analysis, laboratory analysis and life science applications. The company is also expanding the role of digitalization, automation and AI to improve application readiness and solution delivery.

Application-focused exchanges during the event reinforced the same point. In discussions on environmental, industrial and laboratory scenarios, customers focused not only on performance metrics, but also on regulatory fit, workflow integration, long-term operation under complex conditions, and the ability of solutions to function reliably once deployed. These are increasingly central criteria in global purchasing decisions.

The clearest proof came from real-world settings. At the Hangzhou Ecological Environment Monitoring Center, visitors saw FPI’s automated water quality laboratory in operation, where sample handling, workflow continuity and data generation are integrated into day-to-day use. For customers, this offered a more concrete view of how a solution performs not just in demonstration, but in routine operation.

Taken together, the event underscored a broader industry reality: global competition in scientific instruments is increasingly defined not only by what a product can do, but by whether a company can manufacture it at scale, deploy it effectively, support it locally and sustain performance over time. That broader operational capability is becoming a decisive part of how international customers evaluate suppliers.

View original content:https://www.prnewswire.com/news-releases/global-customers-are-taking-a-closer-look-at-focused-photonics-inc-302753822.html

SOURCE Focused Photonics Inc.

Continue Reading

Technology

Straits Financial Services Pte Ltd Granted Overseas Intermediary Futures Broker Status by Shanghai Futures Exchange and Guangzhou Futures Exchange

Published

on

By

SINGAPORE, April 27, 2026 /PRNewswire/ — Straits Financial Services Pte Ltd (“SFSPL”), a member of Straits Financial Group, is pleased to announce that it has been granted overseas intermediary (OI) futures broker status by the Shanghai Futures Exchange (SHFE) and the Guangzhou Futures Exchange (GFEX).

This recognition marks an important milestone in expanding international access to China’s futures markets and further strengthens SFSPL’s ability to connect global investors with onshore opportunities.

As an overseas intermediary futures broker, SFSPL will be able to facilitate client access to selected products listed on SHFE and GFEX. The overseas intermediary model significantly lowers barriers to entry for international participants by removing the need for complex onshore structures and enabling more efficient cross-border access, while operating within China’s regulated market environment.

“As China’s futures market continues to open up, this recognition represents a meaningful milestone for both SFSPL and our clients,” said Roger Quek, Chief Executive Officer and Managing Director, Straits Financial Services Pte Ltd. “We are pleased to support international investors with more seamless access to China’s onshore derivatives market, while maintaining a strong focus on risk management, compliance, and execution efficiency.”

As China’s derivatives market continue to evolve, SFSPL is strongly positioned to support clients looking to deepen their involvement in this high-potential market.

SFSPL remains committed to delivering robust trading capabilities, seamless market access, and trusted expertise to help clients navigate global investment opportunities.

About Straits Financial Services Pte Ltd

At Straits Financial Services Pte Ltd, we distinguish ourselves by promoting key and innovative contracts to support the financial and commodity derivative markets as well as providing products and services to fulfill the needs of every trader.

With a strong presence in Asia and a deep understanding of the global markets, we provide value to our clients by enabling global access with a local perspective. Established in 2010, Straits Financial Services Pte Ltd is part of Straits Financial Group which is headquartered in Singapore.

Straits Financial Services Pte Ltd provides a fully-integrated service for our clients to access the financial and commodity derivative markets and we strive to build lasting relationships with our clients.

For more information, please visit our website at https://www.straitsfinancial.com.

This document is issued for information purposes only. This document is not intended and should not under any circumstances to be construed as an offer or solicitation to buy or sell, nor financial advice or recommendation in relation to any capital market product. All the information contained herein is based on publicly available information and has been obtained from sources that Straits Financial Services Pte Ltd believes to be reliable and correct at the time of publishing this document.

Straits Financial Services Pte Ltd will not be liable for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind) suffered due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information. Past performance or historical record of futures contracts, derivatives contracts, and commodities is not indicative of the future performance. The information in this document is subject to change without notice.

If after reading the foregoing content you have any doubts in relation thereto, please consult your own independent legal, financial and/or professional adviser.

View original content:https://www.prnewswire.com/apac/news-releases/straits-financial-services-pte-ltd-granted-overseas-intermediary-futures-broker-status-by-shanghai-futures-exchange-and-guangzhou-futures-exchange-302752994.html

SOURCE Straits Financial

Continue Reading

Trending